All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The standard of care first-line treatment of adult patients with acute myeloid leukemia (AML) remains induction chemotherapy with cytarabine and an anthracycline, for example, daunorubicin.1 Thrombocytopenia is often present in patients with AML, and this associated symptom can also be exacerbated by induction chemotherapy.2 The oral thrombopoietin receptor agonist, eltrombopag, has been shown to stimulate platelet production via a similar biological mechanism to endogenous thrombopoietin, suggesting a potential treatment for thrombocytopenia.3
This randomized, double-blind, multicenter, phase II study (NCT01890746) aimed to assess the safety and efficacy of eltrombopag in eligible treatment-naïve adult patients with AML (n = 149), during anthracycline-based induction chemotherapy. Standard induction chemotherapy was administered to patients (n = 148), consisting of daunorubicin (90 mg/m2 [18–60 years], 60 mg/m2 [>60 years], days 1–3) in combination with cytarabine (100 mg/m2, days 1–7). Patients were assigned 1:1 to receive either eltrombopag (200 mg, once daily, n = 74) or matching placebo (once daily, n = 74), starting on day four of induction chemotherapy, until one of the following endpoints were met: platelet counts were ≥ 200 x 109/L, remission, or > 42 days from start of induction chemotherapy treatment.
All data is shown as eltrombopag group versus placebo group, where applicable
This phase II study concluded that the combination of eltrombopag and induction chemotherapy has no clinical benefit over placebo in patients with AML, with the safety analysis highlighting that eltrombopag increased the rate of serious adverse events.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox